0000899243-18-002932.txt : 20180205 0000899243-18-002932.hdr.sgml : 20180205 20180205190009 ACCESSION NUMBER: 0000899243-18-002932 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180201 FILED AS OF DATE: 20180205 DATE AS OF CHANGE: 20180205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rubin Karuna CENTRAL INDEX KEY: 0001730419 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34655 FILM NUMBER: 18575748 MAIL ADDRESS: STREET 1: C/O AVEO PHARMACEUTICALS, INC. STREET 2: ONE BROADWAY, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVEO PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001325879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617- 531-2130 MAIL ADDRESS: STREET 1: ONE BROADWAY STREET 2: 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-02-01 0 0001325879 AVEO PHARMACEUTICALS INC AVEO 0001730419 Rubin Karuna C/O AVEO PHARMACEUTICALS, INC. ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 0 1 0 0 Senior VP and General Counsel Stock Option (right to buy) 1.59 2025-07-06 Common Stock 35000 D Stock Option (right to buy) 1.08 2026-01-06 Common Stock 30000 D Stock Option (right to buy) 0.92 2026-05-25 Common Stock 100000 D Stock Option (right to buy) 0.60 2027-02-07 Common Stock 100000 D Stock Option (right to buy) 0.60 2027-02-07 Common Stock 33333 D This option vested as to 25% of the shares underlying such option on July 7, 2016 and the remaining 75% vests in equal monthly installments through July 7, 2019. This option vests in equal monthly installments beginning February 7, 2016 through January 7, 2020. This option vests in equal monthly installments beginning June 26, 2016 through May 26, 2020. This option vests in equal monthly installments beginning March 8, 2017 through February 8, 2021. On February 8, 2017, the reporting person was granted an option to purchase 50,000 shares of common stock. Subject to the achievement of three performance milestones relating to the company's clinical trials and regulatory filings, one third of the option vests on February 8, 2018, and two thirds of the option vests on February 8, 2019. On June 21, 2017, the first two performance milestones were met. As a result, one third of the option will vest on February 8, 2018, and one third of the option will vest on February 8, 2019, in each case subject to the reporting person's continued service to the company. /s/ Karuna Rubin 2018-02-05